{"id":2428,"date":"2018-10-14T09:00:32","date_gmt":"2018-10-14T08:00:32","guid":{"rendered":"http:\/\/fight-malaria-blog.local\/?p=2428"},"modified":"2020-04-21T18:25:58","modified_gmt":"2020-04-21T17:25:58","slug":"five-minutes-with-dr-deborah-oneil-the-post-antibiotic-era","status":"publish","type":"post","link":"https:\/\/fight-malaria-blog.local\/five-minutes\/five-minutes-with-dr-deborah-oneil-the-post-antibiotic-era\/","title":{"rendered":"Five Minutes with Dr Deborah O&#8217;Neil | The Post-Antibiotic Era"},"content":{"rendered":"<!--[if lt IE 9]><script>document.createElement('audio');<\/script><![endif]-->\n<audio class=\"wp-audio-shortcode\" id=\"audio-2428-1\" preload=\"none\" style=\"width: 100%;\" controls=\"controls\"><source type=\"audio\/mpeg\" src=\"https:\/\/d3ctxlq1ktw2nl.cloudfront.net\/production\/2018-9-13\/5130094-44100-2-bae578d0ea914.m4a?_=1\" \/><a href=\"https:\/\/d3ctxlq1ktw2nl.cloudfront.net\/production\/2018-9-13\/5130094-44100-2-bae578d0ea914.m4a\">https:\/\/d3ctxlq1ktw2nl.cloudfront.net\/production\/2018-9-13\/5130094-44100-2-bae578d0ea914.m4a<\/a><\/audio>\n<p>Podcast Available on\u00a0<strong><a href=\"https:\/\/itunes.apple.com\/us\/podcast\/five-minutes\/id1406200338?mt=2\" target=\"_blank\" rel=\"noopener noreferrer\">iTunes<\/a><\/strong>\u00a0and\u00a0<a href=\"https:\/\/open.spotify.com\/show\/2oBrfg0c28be1dMjTxoSc1\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Spotify<\/strong>.<\/a><\/p>\n<hr \/>\n<p>Welcome back.<\/p>\n<p>Joining me today is Dr Deborah O\u2019Neil, the CEO of <a href=\"https:\/\/www.novabiotics.co.uk\/\" target=\"_blank\" rel=\"noopener noreferrer\">Novabiotics<\/a>, a leading clinical-stage biotechnology company focused on the design and development of first-in-class anti-infectives.<\/p>\n<p>She recently delivered a talk on the pharmaceutical industry as it is today, and offered an insight into what it could become, with a focus on so-called \u2018personalised medicines\u2019. She also addressed the worrying issue of antimicrobial resistance and discussed <a href=\"https:\/\/www.theguardian.com\/science\/2018\/apr\/26\/nhs-car-t-game-changing-cancer-treatment-immune-therapy\" target=\"_blank\" rel=\"noopener noreferrer\">new cancer therapies being approved by the NHS<\/a>.<\/p>\n<p><strong>And she\u2019s here with me now. Deborah, thanks for joining me.<\/strong><\/p>\n<p>Great to be here, pleasure.<\/p>\n<p><strong>In your speech, you discussed how the drugs which we use every day, so paracetamol and aspirin, wouldn&#8217;t be approved today due to their safety profiles. Do you think that this increased focus on the safety of drugs is perhaps blocking new, innovative and potentially life-saving treatments from being approved?<\/strong><\/p>\n<p>I don&#8217;t think it is blocking, it does make it a little bit more challenging to develop these very new therapies but I would say the regulatory agencies are very much prepared to work hand in hand with the companies that are developing them. They are on the same side and they are there to get new and more innovative medicines onto the market. But for sure, safety is first and foremost, efficacy second. As I mentioned in the talk, also more emphasis on how the drug actually works, more information about its mechanism of action, which is going to be linked to the safety and the efficacy anyway but something that in the past wasn&#8217;t necessarily a focus.<\/p>\n<p><strong>And you mentioned in your talk that you think that over the past five years we&#8217;ve seen a shift in the pharmaceutical industry from focusing on profits to focusing on the patient. Would that be a fair understanding of this shift?<\/strong><\/p>\n<p>Yes, I think so. The emphasis more on precision, personalised medicine, not mass market drugs that you want to get out there for everyone to take, the new pricing models that I mentioned as well. Even though profit absolutely is still important and essential because there won&#8217;t be a pipeline without it, it&#8217;s access. I think it&#8217;s all about market access, patient access and it&#8217;s absolutely much more front and centre in the industry now.<\/p>\n<p><strong>And talking more about those personalised medicines, like the cancer CAR-T therapy where your re-engineering the body&#8217;s immune cells, where do you see this progression heading in the future?<\/strong><\/p>\n<p>Much more as a focus of drugs that we will all be taking. So, rather than I guess pharmacology and chemical-based drugs, biological therapies and those that are targeted, not just to the\u00a0disease but that particular patient&#8217;s disease, will become more and more commonplace. Lots and lots of clinical trials of these, lots of them are in development. I think we&#8217;ll see an exponential growth of that type of medicine. Again, the regulators are working alongside the companies because progress is very rapid. Things like the pricing of those therapies as well because, if you think about it, you&#8217;re making one therapy that only works for one patient in the world, how do you price that? But these first drugs have already got through those barriers and paved the way for other ones. Those are going to be the future of medicine in a number of conditions for sure.<\/p>\n<p><strong>And going back to those drugs which we use every day and in hospitals, if we don&#8217;t start to create new drugs now to replace those what sort of impact are we going to see when resistance to those drugs grows?<\/strong><\/p>\n<p>A major problem. In some areas, so cancer which I talked about, the future is looking very bright. There&#8217;s a lot of developments, a lot of progress, these exciting new medicines are really focused. Where we&#8217;ve taken our eye off the ball, as an industry, is drug pricing and incentives to develop these therapies is in the infection space. It is very scary what could happen if there is no intervention in this. This fairly bleak landscape where we&#8217;re not seeing any new novel classes coming through. I think a lot of those barriers are now falling away, people are now very aware of the consequences in the future if we&#8217;re looking at effectively a post-antibiotic era.<\/p>\n<p><strong>Dr Deborah O\u2019Neil, thank you. <\/strong><\/p>\n<p>Pleasure, thank you.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Dr Deborah O&#8217;Neil is the CEO of Novabiotics, a leading clinical-stage biotechnology company. She talks to me about antibiotic resistance and the future of pharma with so-called &#8216;personalised medicines&#8217;.<\/p>\n","protected":false},"author":1,"featured_media":2429,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false},"categories":[8],"tags":[35,27,20,23],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v19.14 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Five Minutes with Dr Deborah O&#039;Neil | The Post-Antibiotic Era<\/title>\n<meta name=\"description\" content=\"Dr Deborah O&#039;Neil is the CEO of Novabiotics. She talks to me about antibiotic resistance and the future of pharma with so-called &#039;personalised medicines&#039;.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/fight-malaria-blog.local\/five-minutes\/five-minutes-with-dr-deborah-oneil-the-post-antibiotic-era\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Five Minutes with Dr Deborah O&#039;Neil | The Post-Antibiotic Era\" \/>\n<meta property=\"og:description\" content=\"Dr Deborah O&#039;Neil is the CEO of Novabiotics. She talks to me about antibiotic resistance and the future of pharma with so-called &#039;personalised medicines&#039;.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/fight-malaria-blog.local\/five-minutes\/five-minutes-with-dr-deborah-oneil-the-post-antibiotic-era\/\" \/>\n<meta property=\"og:site_name\" content=\"The Fight Malaria Blog\" \/>\n<meta property=\"article:published_time\" content=\"2018-10-14T08:00:32+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-04-21T17:25:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/fight-malaria-blog.local\/wp-content\/uploads\/2019\/02\/Five_Minutes_with_Dr_Deborah_O_Neil_The_Post-Antibiotic_Era_dyzzdr.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"500\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Thomas Locke\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Thomas Locke\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/fight-malaria-blog.local\/five-minutes\/five-minutes-with-dr-deborah-oneil-the-post-antibiotic-era\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/fight-malaria-blog.local\/five-minutes\/five-minutes-with-dr-deborah-oneil-the-post-antibiotic-era\/\"},\"author\":{\"name\":\"Thomas Locke\",\"@id\":\"https:\/\/fight-malaria-blog.local\/#\/schema\/person\/866d37307e013f5a16202221b93ef75a\"},\"headline\":\"Five Minutes with Dr Deborah O&#8217;Neil | The Post-Antibiotic Era\",\"datePublished\":\"2018-10-14T08:00:32+00:00\",\"dateModified\":\"2020-04-21T17:25:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/fight-malaria-blog.local\/five-minutes\/five-minutes-with-dr-deborah-oneil-the-post-antibiotic-era\/\"},\"wordCount\":759,\"publisher\":{\"@id\":\"https:\/\/fight-malaria-blog.local\/#organization\"},\"keywords\":[\"Interviews\",\"Medicine\",\"New Technologies\",\"Research &amp; Development\"],\"articleSection\":[\"Five Minutes\"],\"inLanguage\":\"en-GB\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/fight-malaria-blog.local\/five-minutes\/five-minutes-with-dr-deborah-oneil-the-post-antibiotic-era\/\",\"url\":\"https:\/\/fight-malaria-blog.local\/five-minutes\/five-minutes-with-dr-deborah-oneil-the-post-antibiotic-era\/\",\"name\":\"Five Minutes with Dr Deborah O'Neil | The Post-Antibiotic Era\",\"isPartOf\":{\"@id\":\"https:\/\/fight-malaria-blog.local\/#website\"},\"datePublished\":\"2018-10-14T08:00:32+00:00\",\"dateModified\":\"2020-04-21T17:25:58+00:00\",\"description\":\"Dr Deborah O'Neil is the CEO of Novabiotics. She talks to me about antibiotic resistance and the future of pharma with so-called 'personalised medicines'.\",\"breadcrumb\":{\"@id\":\"https:\/\/fight-malaria-blog.local\/five-minutes\/five-minutes-with-dr-deborah-oneil-the-post-antibiotic-era\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/fight-malaria-blog.local\/five-minutes\/five-minutes-with-dr-deborah-oneil-the-post-antibiotic-era\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/fight-malaria-blog.local\/five-minutes\/five-minutes-with-dr-deborah-oneil-the-post-antibiotic-era\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/fight-malaria-blog.local\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Five Minutes with Dr Deborah O&#8217;Neil | The Post-Antibiotic Era\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/fight-malaria-blog.local\/#website\",\"url\":\"https:\/\/fight-malaria-blog.local\/\",\"name\":\"The Fight Malaria Blog\",\"description\":\"Malaria News, Views and Interviews.\",\"publisher\":{\"@id\":\"https:\/\/fight-malaria-blog.local\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/fight-malaria-blog.local\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/fight-malaria-blog.local\/#organization\",\"name\":\"Fight Malaria\",\"url\":\"https:\/\/fight-malaria-blog.local\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/fight-malaria-blog.local\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/fight-malaria-blog.local\/wp-content\/uploads\/2020\/07\/blog_logo-20200728-212450.svg\",\"contentUrl\":\"https:\/\/fight-malaria-blog.local\/wp-content\/uploads\/2020\/07\/blog_logo-20200728-212450.svg\",\"caption\":\"Fight Malaria\"},\"image\":{\"@id\":\"https:\/\/fight-malaria-blog.local\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/fight-malaria-blog.local\/#\/schema\/person\/866d37307e013f5a16202221b93ef75a\",\"name\":\"Thomas Locke\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/fight-malaria-blog.local\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/4e07b1fc2fb741436038290480c02087?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/4e07b1fc2fb741436038290480c02087?s=96&d=mm&r=g\",\"caption\":\"Thomas Locke\"},\"url\":\"https:\/\/fight-malaria-blog.local\/author\/fightmalaria\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Five Minutes with Dr Deborah O'Neil | The Post-Antibiotic Era","description":"Dr Deborah O'Neil is the CEO of Novabiotics. She talks to me about antibiotic resistance and the future of pharma with so-called 'personalised medicines'.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/fight-malaria-blog.local\/five-minutes\/five-minutes-with-dr-deborah-oneil-the-post-antibiotic-era\/","og_locale":"en_GB","og_type":"article","og_title":"Five Minutes with Dr Deborah O'Neil | The Post-Antibiotic Era","og_description":"Dr Deborah O'Neil is the CEO of Novabiotics. She talks to me about antibiotic resistance and the future of pharma with so-called 'personalised medicines'.","og_url":"https:\/\/fight-malaria-blog.local\/five-minutes\/five-minutes-with-dr-deborah-oneil-the-post-antibiotic-era\/","og_site_name":"The Fight Malaria Blog","article_published_time":"2018-10-14T08:00:32+00:00","article_modified_time":"2020-04-21T17:25:58+00:00","og_image":[{"width":800,"height":500,"url":"https:\/\/fight-malaria-blog.local\/wp-content\/uploads\/2019\/02\/Five_Minutes_with_Dr_Deborah_O_Neil_The_Post-Antibiotic_Era_dyzzdr.jpg","type":"image\/jpeg"}],"author":"Thomas Locke","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Thomas Locke","Estimated reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/fight-malaria-blog.local\/five-minutes\/five-minutes-with-dr-deborah-oneil-the-post-antibiotic-era\/#article","isPartOf":{"@id":"https:\/\/fight-malaria-blog.local\/five-minutes\/five-minutes-with-dr-deborah-oneil-the-post-antibiotic-era\/"},"author":{"name":"Thomas Locke","@id":"https:\/\/fight-malaria-blog.local\/#\/schema\/person\/866d37307e013f5a16202221b93ef75a"},"headline":"Five Minutes with Dr Deborah O&#8217;Neil | The Post-Antibiotic Era","datePublished":"2018-10-14T08:00:32+00:00","dateModified":"2020-04-21T17:25:58+00:00","mainEntityOfPage":{"@id":"https:\/\/fight-malaria-blog.local\/five-minutes\/five-minutes-with-dr-deborah-oneil-the-post-antibiotic-era\/"},"wordCount":759,"publisher":{"@id":"https:\/\/fight-malaria-blog.local\/#organization"},"keywords":["Interviews","Medicine","New Technologies","Research &amp; Development"],"articleSection":["Five Minutes"],"inLanguage":"en-GB"},{"@type":"WebPage","@id":"https:\/\/fight-malaria-blog.local\/five-minutes\/five-minutes-with-dr-deborah-oneil-the-post-antibiotic-era\/","url":"https:\/\/fight-malaria-blog.local\/five-minutes\/five-minutes-with-dr-deborah-oneil-the-post-antibiotic-era\/","name":"Five Minutes with Dr Deborah O'Neil | The Post-Antibiotic Era","isPartOf":{"@id":"https:\/\/fight-malaria-blog.local\/#website"},"datePublished":"2018-10-14T08:00:32+00:00","dateModified":"2020-04-21T17:25:58+00:00","description":"Dr Deborah O'Neil is the CEO of Novabiotics. She talks to me about antibiotic resistance and the future of pharma with so-called 'personalised medicines'.","breadcrumb":{"@id":"https:\/\/fight-malaria-blog.local\/five-minutes\/five-minutes-with-dr-deborah-oneil-the-post-antibiotic-era\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/fight-malaria-blog.local\/five-minutes\/five-minutes-with-dr-deborah-oneil-the-post-antibiotic-era\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/fight-malaria-blog.local\/five-minutes\/five-minutes-with-dr-deborah-oneil-the-post-antibiotic-era\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/fight-malaria-blog.local\/"},{"@type":"ListItem","position":2,"name":"Five Minutes with Dr Deborah O&#8217;Neil | The Post-Antibiotic Era"}]},{"@type":"WebSite","@id":"https:\/\/fight-malaria-blog.local\/#website","url":"https:\/\/fight-malaria-blog.local\/","name":"The Fight Malaria Blog","description":"Malaria News, Views and Interviews.","publisher":{"@id":"https:\/\/fight-malaria-blog.local\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/fight-malaria-blog.local\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-GB"},{"@type":"Organization","@id":"https:\/\/fight-malaria-blog.local\/#organization","name":"Fight Malaria","url":"https:\/\/fight-malaria-blog.local\/","logo":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/fight-malaria-blog.local\/#\/schema\/logo\/image\/","url":"https:\/\/fight-malaria-blog.local\/wp-content\/uploads\/2020\/07\/blog_logo-20200728-212450.svg","contentUrl":"https:\/\/fight-malaria-blog.local\/wp-content\/uploads\/2020\/07\/blog_logo-20200728-212450.svg","caption":"Fight Malaria"},"image":{"@id":"https:\/\/fight-malaria-blog.local\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/fight-malaria-blog.local\/#\/schema\/person\/866d37307e013f5a16202221b93ef75a","name":"Thomas Locke","image":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/fight-malaria-blog.local\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/4e07b1fc2fb741436038290480c02087?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/4e07b1fc2fb741436038290480c02087?s=96&d=mm&r=g","caption":"Thomas Locke"},"url":"https:\/\/fight-malaria-blog.local\/author\/fightmalaria\/"}]}},"_links":{"self":[{"href":"https:\/\/fight-malaria-blog.local\/wp-json\/wp\/v2\/posts\/2428"}],"collection":[{"href":"https:\/\/fight-malaria-blog.local\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/fight-malaria-blog.local\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/fight-malaria-blog.local\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/fight-malaria-blog.local\/wp-json\/wp\/v2\/comments?post=2428"}],"version-history":[{"count":0,"href":"https:\/\/fight-malaria-blog.local\/wp-json\/wp\/v2\/posts\/2428\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/fight-malaria-blog.local\/wp-json\/wp\/v2\/media\/2429"}],"wp:attachment":[{"href":"https:\/\/fight-malaria-blog.local\/wp-json\/wp\/v2\/media?parent=2428"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/fight-malaria-blog.local\/wp-json\/wp\/v2\/categories?post=2428"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/fight-malaria-blog.local\/wp-json\/wp\/v2\/tags?post=2428"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}